IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.53▼ 0.13% USD/CLP994.16▼ 0.13% USD/COP3,302▼ 0.37% USD/PEN3.40▼ 0.09% USD/ARS1,544▼ 0.02% USD/UYU40.59▲ 3.32% USD/PYG6,196▲ 3.06% USD/BOB11.59▲ 2.15% USD/DOP60.59▲ 0.26% USD/CRC442.74▲ 1.24% USD/GTQ7.64▲ 3.24% USD/HNL26.91▲ 3.28% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 2.75% USD/TTD6.75▲ 2.58% EUR/BRL6.24▲ 0.29% BRENT 95.71 ▼ 0.14% WTI 88.68 ▲ 0.14% IRON ORE 161.91 — — COPPER 6.07 ▼ 0.16% GOLD 3,892 ▲ 0.16% SILVER 48.66 ▼ 0.76% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.53 ▼ 0.14% USD/CLP 994.16 ▼ 0.13% USD/COP 3,302 ▼ 0.37% USD/PEN 3.40 ▼ 0.09% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 ▲ 3.32% USD/PYG 6,196 ▲ 3.06% USD/BOB 11.59 ▲ 2.15% USD/DOP 60.59 ▲ 0.26% USD/CRC 442.74 ▲ 1.24% USD/GTQ 7.64 ▲ 3.24% USD/HNL 26.91 ▲ 3.28% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.24 ▲ 0.29% BRENT 95.71 ▼ 0.14% WTI 88.68 ▲ 0.14% IRON ORE 161.91 — — COPPER 6.07 ▼ 0.16% GOLD 3,892 ▲ 0.16% SILVER 48.66 ▼ 0.76% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Earnings Market Reports

RD Saúde Struggles With Profitability in Q1 2025 as Market Share Gains Fail to Offset Costs

RD Saúde (RADL3), Brazil’s largest pharmacy chain, saw its shares plummet 7.9% to R$17.91 ($3.00) on May 7 after reporting weaker-than-expected...

By RT Staff Reporters · · 2 min read
RD Saúde Struggles With Profitability in Q1 2025 as Market Share Gains Fail to Offset Costs
Photo: Rafael Matsunaga, CC BY 2.0, via Wikimedia Commons

RD Saúde (RADL3), Brazil’s largest pharmacy chain, saw its shares plummet 7.9% to R$17.91 ($3.00) on May 7 after reporting weaker-than-expected first-quarter earnings.

The operator of DrogaRaia and Drogasil stores posted a 17% annual decline in net income to R$177.1 million ($29.5 million), despite a 10.8% revenue increase to R$10.8 billion ($1.8 billion).

Adjusted EBITDA fell 5.3% to R$644 million ($107 million), with margins shrinking to 6% as rising labor costs and aggressive promotions squeezed profitability. The company burned R$123.8 million ($20.6 million) in free cash flow during the quarter, compounding concerns about its expansion strategy.

Free daily brief — no card needed
Get every Market Reports story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

RD Saúde opened 75 new stores, reaching 3,301 locations nationwide, but same-store sales growth slowed to 5.4% from 9.6% a year earlier. Analysts cited weaker demand for cosmetics and hygiene products as a key drag.

They also pointed to fewer dengue fever cases compared to 2024 and calendar effects from the leap year. Market share edged up 0.4 percentage points to 16.6%, though gains came at the cost of margin erosion.

RD Saúde Struggles With Profitability in Q1 2025 as Market Share Gains Fail to Offset Costs
RD Saúde Struggles With Profitability in Q1 2025 as Market Share Gains Fail to Offset Costs.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Goldman Sachs maintained a buy rating with a R$25.00 ($4.17) price target, betting on digital investments and a planned 330-350 new stores in 2025. Conversely, Itaú BBA warned of further earnings downgrades, noting net income missed consensus by 23%.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Exxon gets Guyana approval for a gas project”

RD Saúde Faces Margin Pressures

BTG Pactual called Q1 a “low point” but retained its buy recommendation, highlighting RD Saúde’s 2.8% reduction in administrative costs as a rare bright spot.

The results arrive as Brazil’s R$39.3 billion ($6.6 billion) generic drug market grows at 6.4% annually through 2033, driven by patent expirations and government cost-cutting initiatives.

However, intensifying competition from online pharmacies and physical rivals threatens RD Saúde’s dominance. Investors now question whether the firm’s R$1.22 billion ($203 million) annual free cash flow can sustain both dividend payouts and its aggressive store rollout.

Shares have fallen 18% year-to-date, underperforming the Ibovespa’s 2.5% decline. With seven analysts rating the stock a buy, seven neutral, and three sell, the divided outlook reflects uncertainty about Brazil’s pharmaceutical retail sector.

RD Saúde’s next challenge: proving its digital platforms and omnichannel strategy can offset margin pressures from government-mandated drug price controls taking effect later this year.

Live Company IntelligenceRaia Drogasil S.A — the full investor dossierCompany overview and the latest Rio Times coverage.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Read More from The Rio Times

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Exxon gets Guyana approval for a gas project”

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.